Recommendations

100
Smith et al. 2005
ACC/AHA/SCAI Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
SCAI - www.scai.org
J Cardiol 2002;90:1062-7.
229. Gaxiola E, Vlietsra R, Browne KF, et al. Is the outcome of coronary
stenting worse in elderly patients? J Interven Cardiol
1998;11:37-40.
230. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous
interventional outcomes for patients with diabetes mellitus: results
of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting
trial) diabetic substudy. Circulation 1999;100:2477-84.
231. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet
glycoprotein IIb/IIIa receptor inhibitors among diabetic patients
undergoing percutaneous coronary intervention: : Do Tirofiban
and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-
year follow-up. Circulation 2002;105:2730-6.
232. Brooks RC, Detre KM. Clinical trials of revascularization therapy
in diabetics. Curr Opin Cardiol 2000;15:287-92.
233. Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous
coronary-artery bypass surgery on the prognosis of patients
with diabetes who have acute myocardial infarction. Bypass
Angioplasty Revascularization Investigation Investigators. N
Engl J Med 2000;342:989-97.
234. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A
hierarchical Bayesian meta-analysis of randomised clinical trials
of drug-eluting stents. Lancet 2004;364:583-91.
235. Schofer J, Schluter M. Are drug-eluting stents a panacea for
patients with coronary heart disease? Lancet 2004;364:558-9.
236. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization
of sirolimus-eluting stents compared with conventional
bare stent implantation in the “real world”: the Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) registry. Circulation 2004;109:190-5.
237. Future Revascularization Evaluation in Patients with Diabetes
Mellitus: Optimal Management of Multivessel Disease. National
Library of Medicine. Available at http://www.clinicaltrials.gov/
ct/gui/show/NCT00086450,.Last update 6-30-2005.
238. Corpus RA, George PB, House JA, et al. Optimal glycemic control
is associated with a lower rate of target vessel revascularization
in treated type II diabetic patients undergoing elective percutaneous
coronary intervention. J Am Coll Cardiol 2004;43:8-14.
239. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG,
Thorgeirsson G. Cholesterol lowering with simvastatin improves
prognosis of diabetic patients with coronary heart disease. A subgroup
analysis of the Scandinavian Simvastatin Survival Study
(4S). Diabetes Care 1997;20:614-20.
240. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial
cholesterol levels. The Long-Term Intervention with Pravastatin
in Ischaemic Disease (LIPID) Study Group. N Engl J Med
1998;339:1349-57.
241. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events
and their reduction with pravastatin in diabetic and glucose-intolerant
myocardial infarction survivors with average cholesterol levels:
subgroup analyses in the cholesterol and recurrent events
(CARE) trial. The Care Investigators. Circulation 1998;98:2513-9.
242. MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled
trial. Lancet 2002;360:7-22.
243. Holmes DRJ, Topol EJ, Califf RM, et al. A multicenter, randomized
trial of coronary angioplasty versus directional atherectomy
for patients with saphenous vein bypass graft lesions: CAVEAT-II
Investigators. Circulation 1995;91:1966-74.
244. Pomerantz RM, Kuntz RE, Carrozza JP, et al. Acute and longterm
outcome of narrowed saphenous venous grafts treated by
endoluminal stenting and directional atherectomy. Am J Cardiol
1992;70:161-7.
245. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late
outcomes after stent implantation in saphenous vein graft lesions:
the multicenter U.S. Palmaz-Schatz stent experience. The
Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995;26:
704-12.
246. Brener SJ, Ellis SG, Apperson-Hansen C, Leon MB, Topol EJ.
Comparison of stenting and balloon angioplasty for narrowings in
aortocoronary saphenous vein conduits in place for more than five
years. Am J Cardiol 1997;79:13-8.
247. Gruberg L, Dangas G, Mehran R, et al. Percutaneous revascularization
of the internal mammary artery graft: short- and long-term
outcomes. J Am Coll Cardiol 2000;35:944-8.
248. Lopez JJ, Ho KK, Stoler RC, et al. Percutaneous treatment of protected
and unprotected left main coronary stenoses with new
devices: immediate angiographic results and intermediate-term
follow-up. J Am Coll Cardiol 1997;29:345-52.
249. Dorros G, Lewin RF, Mathiak LM. Coronary angioplasty in
patients with prior coronary artery bypass surgery: all prior coronary
artery bypass surgery patients and patients more than 5 years
after coronary bypass surgery. Cardiol Clin 1989;7:791-803.
250. Plokker HW, Meester BH, Serruys PW. The Dutch experience in
percutaneous transluminal angioplasty of narrowed saphenous
veins used for aortocoronary arterial bypass. Am J Cardiol
1991;67:361-6.
251. Webb JG, Myler RK, Shaw RE, et al. Coronary angioplasty after
coronary bypass surgery: initial results and late outcome in 422
patients. J Am Coll Cardiol 1990;16:812-20.
252. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from
intravenous platelet glycoprotein IIb/IIIa receptor inhibition as
adjunctive treatment for percutaneous interventions of aortocoronary
bypass grafts: a pooled analysis of five randomized clinical
trials. Circulation 2002;106:3063-7.
253. Limbruno U, Micheli A, De CM, et al. Mechanical prevention of
distal embolization during primary angioplasty: safety, feasibility,
and impact on myocardial reperfusion. Circulation 2003;108:171-6.
254. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison
of distal protection with a filter-based catheter and a balloon
occlusion and aspiration system during percutaneous intervention
of diseased saphenous vein aorto-coronary bypass grafts.
Circulation 2003;108:548-53.
255. Baim DS, Wahr D, George B, et al. Randomized trial of a distal
embolic protection device during percutaneous intervention of
saphenous vein aorto-coronary bypass grafts. Circulation
2002;105:1285-90.
256. Mathew V, Clavell AL, Lennon RJ, Grill DE, Holmes DRJ.
Percutaneous coronary interventions in patients with prior coronary
artery bypass graft surgery: Changes in patient characteristics
and outcome during two decades. Am J Med 2000;108:127.
257. Bhatt DL, Topol E. Percutaneous coronary intervention for
patients with prior bypass surgery: Therapy in Evolution. Am J
Med 2000;108:176.
258. Teirstein PS, Warth DC, Haq N, et al. High speed rotational coronary
atherectomy for patients with diffuse coronary artery disease.
J Am Coll Cardiol 1991;18:1694-701.
259. Sharma SK, Dangas G, Mehran R, et al. Risk factors for the development
of slow flow during rotational coronary atherectomy. Am
J Cardiol 1997;80:219-22.
260. Dehmer GJ, Nichols TC, Bode AP, et al. Assessment of platelet
activation by coronary sinus blood sampling during balloon
angioplasty and directional coronary atherectomy. Am J Cardiol